Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform

Stopped The trial was revised to be two protocols, one Prevention, one Eradication Trials.

Conditions

• Severe Hemophilia A

Interventions

• DRUG: Eloctate Prophylaxis
• DRUG: Emicizumab Prophylaxis
• DRUG: Eloctate ITI plus Emicizumab
• DRUG: Eloctate ITI

Sponsor

Margaret Ragni